Mechanisms of Parkinson's Disease Linked to Pathological α-Synuclein: New Targets for Drug Discovery

Neuron

Volumn 52, Issue 1, 2006, Pages 33-38

  Lee, Virginia M Y ^a   Trojanowski, John Q ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

BEHAVIOR DISORDER; CENTRAL NERVOUS SYSTEM; DEMENTIA; DISEASE COURSE; DOPAMINOCHROME; DRUG TARGETING; GENE LOCUS; GENE MUTATION; GENETIC LINKAGE; HUMAN; LEWY BODY; MOTOR DYSFUNCTION; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; REVIEW; SUBSTANTIA NIGRA;

ALPHA-SYNUCLEIN; ANIMALS; DRUG DESIGN; HUMANS; LEWY BODIES; MODELS, MOLECULAR; MUTATION; PARKINSON DISEASE; SENILE PLAQUES;

EID: 33749240943     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuron.2006.09.026     Document Type: Review

References (31)

1. Abdi F., Quinn J.F., Jankovic J., McIntosh M., Leverenz J.B., Peskind E., Nixon R., Nutt J., Chung K., Zabetian C., et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J. Alzheimers Dis. 9 (2006) 293-348
2. Bilen J., and Bonini N.M. Drosophila as a model for human neurodegenerative disease. Annu. Rev. Genet. 39 (2005) 153-171
3. Chandra S., Gallardo G., Fernadez-Chacon R., Schluter O.M., and Sudhof T.C. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 123 (2005) 383-396
4. Chartier-Harlin M.C., Kachergus J., Roumier C., Mouroux V., Douay X., Lincoln S., Levecque C., Larvor L., Andrieux J., Hulihan M., et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364 (2004) 1167-1169
5. Conway K.A., Rochet J.C., Bieganski R.M., and Lansbury Jr. P.T. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294 (2001) 1346-1349
6. Cookson M.R. The biochemistry of Parkinson's disease. Annu. Rev. Biochem. 74 (2005) 29-52
7. Cooper A.A., Gitler A.D., Cashikar A., Haynes C.M., Hill K.J., Bhullar B., Liu K., Xu K., Strathearn K.E., Liu F., et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313 (2006) 324-328
8. Cuervo A.M., Stefanis L., Fredenburg R., Lansbury P.T., and Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305 (2004) 1292-1295
9. Fan Y., Limprasert P., Murray I.V.J., Smith A.C., Lee V.M.-Y., Trojanowski J.Q., Sopher B.L., and La Spada A.R. Beta-synuclein modulates alpha-synuclein neurotoxicity by reducing alpha-synuclein protein expression. Hum. Mol. Genet. (2006) in press
10. Feany M.B. New genetic insights into Parkinson's disease. N. Engl. J. Med. 351 (2004) 1937-1940
11. Forman M.S., Lee V.M.-Y., and Trojanowski J.Q. Nosology of Parkinson's disease: Looking for the way out of a quagmire. Neuron 47 (2005) 479-482
12. Giasson B.I., Lee V.M.-Y., and Trojanowski J.Q. Animal models of neurodegenerative dementing disorders other than Alzheimer's disease. Clin. Neurosci. Res. 3 (2004) 427-436
13. Giasson B.I., Lee V.M.-Y., and Trojanowski J.Q. Parkinson's disease, dementia with Lewy bodies, multiple system atrophy and the spectrum of diseases with alpha-synuclein inclusions. In: Esiri M., Lee V.M.-Y., and Trojanowski J.Q. (Eds). The Neuropathology Of Dementia (2004), Cambridge University Press, Cambridge 353-375
14. Greenamyre J.T., and Hastings T.G. Parkinson's-divergent causes, convergent mechanisms. Science 304 (2004) 1120-1122
15. Hashimoto M., Rockentein E., Mante M., Mallory M., and Masliah E. Beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron 32 (2001) 213-223
16. Katzenschlager R., Evans A., Manson A., Patsalos P.N., Ratnaraj N., Watt H., Timmermann L., Van der Giessen R., and Lees A.J. Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. J. Neurol. Neurosurg. Psychiatry 75 (2004) 1672-1677
17. Kotzbauer P.T., Giasson B.I., Kravitz A.V., Golbe L.I., Mark M.H., Trojanowski J.Q., and Lee V.M.-Y. Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation. Exp. Neurol. 187 (2004) 279-288
18. Manyam B.V. Paralysis agitans and levodopa in "Ayurveda": ancient Indian medical treatise. Mov. Disord. 5 (1990) 47-48
19. McKeith I.G., Dickson D.W., Lowe J., Emre M., O'Brien J.T., Feldman H., Cummings J., Duda J., Lippa, et al., for the Consortium on DLB. Dementia with Lewy Bodies: Diagnosis and Management: Third Report of the DLB Consortium. Neurology 65 (2005) 1863-1872
20. Norris E.H., Giasson B.I., Hodara R., Xu S., Trojanowski J.Q., Ischiropoulos H., and Lee V.M.-Y. Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome mediated conformational alterations. J. Biol. Chem. 280 (2005) 21212-21219
21. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
22. Rochet J.C., Outeiro T.F., Conway K.A., Ding T.T., Volles M.J., Lashuel H.A., Bieganski R.M., Lindquist S.L., and Lansbury P.T. Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. J. Mol. Neurosci. 23 (2004) 23-34
23. Ronald & Nancy Reagan Institute of the Alzheimer's Association & National Institute on Aging Working Group on Biological Markers of Alzheimer's Disease Disease. Consensus report of the Working Group on Biological Markers of Alzheimer's Disease. Neurobiol. Aging 19 (1998) 109-116
24. Savitt J.M., Dawson V.L., and Dawson T.M. Diagnosis and treatment of Parkinson disease: Molecules to medicine. J. Clin. Invest. 116 (2006) 1744-1754
25. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 302 (2003) 841
26. Skovronsky D.M., Lee V.M.-Y., and Trojanowski J.Q. Neurodegenerative diseases: New concepts of pathogenesis and their therapeutic implications. Annu. Rev. Pathol. Mech. Dis. 1 (2006) 151-170
27. Spillantini M.G., Schmidt M.L., Lee V.M.-Y., Trojanowski J.Q., Jakes R., and Goedert M. Alpha-synuclein in Lewy bodies. Nature 388 (1997) 839-840
28. Thal L.J., Kantarci K., Reiman E.M., Klunk W.E., Weiner M.W., Zetterberg H., Galasko D., Pratico D., Griffin S., Schenk D., and Siemers E. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis. Assoc. Disord. 20 (2006) 6-15
29. Tofaris G.K., Garcia Reitbock P., Humby T., Lambourne S.L., O'Connell M., Ghetti B., Gossage H., Emson P.C., Wilkinson L.S., Goedert M., and Spillantini M.G. Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders. J. Neurosci. 26 (2006) 3942-3950
30. Tokuda T., Salem S.A., Allsop D., Mizuno T., Nakagawa M., Qureshi M.M., Locascio J.J., Schlossmacher M.G., and El-Agnaf O.M. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem. Biophys. Res. Commun. 349 (2006) 162-166
31. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R.J., Calne D.B., et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44 (2004) 601-607